Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is converted in the body to the active metabolite SN‑38, which inhibits the enzyme topoisomerase I. This inhibition prevents the relaxation of DNA strands during replication, leading to accumulation of DNA breaks, disruption of transcription, and ultimately death of rapidly dividing cancer cells.

The dose of Irinotecan Accord is determined individually by the prescribing oncologist based on factors such as the type of cancer, treatment protocol, patient weight, and overall health. Specific dosing regimens are not disclosed here and should follow the prescriber’s instructions.

Irinotecan is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and breastfeeding is not recommended because the drug can be excreted in milk and may harm the infant.

To order Irinotecan Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Irinotecan is a pro‑drug that requires metabolic activation to SN‑38, whereas other topoisomerase I inhibitors such as topotecan are administered in active form. Irinotecan is commonly used for colorectal cancer, while topotecan is often employed for small‑cell lung cancer. Both share similar mechanisms but differ in pharmacokinetics, dosing schedules, and toxicity profiles.

Irinotecan Accord should be stored at 2‑8 °C in a refrigerator, protected from light. The solution must not be frozen or shaken vigorously. Prior to administration, it should be inspected for particulate matter and used within the time frame recommended by the manufacturer.

Irinotecan Accord is given as an intravenous infusion, typically over 30 to 90 minutes depending on the treatment protocol. The infusion is performed by qualified healthcare professionals in a clinical setting, with appropriate monitoring for infusion‑related reactions and vital signs.

The most serious risks include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea or colitis, hepatic toxicity, and hypersensitivity reactions such as anaphylaxis. Patients should be monitored closely for signs of infection, persistent diarrhea, jaundice, or allergic symptoms and seek immediate medical attention if they occur.

Irinotecan Accord should not be used by patients with known hypersensitivity to irinotecan or its excipients, those who are pregnant, or individuals with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment. Use in pediatric patients is not established and should be avoided unless specifically indicated by a specialist.